Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Taiwan study hunts for hidden genetic clues in rare stomach cancer

NCT ID NCT04821895

Knowledge-focused Sponsor: National Health Research Institutes, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study looks at the genetic makeup of a rare stomach cancer called gastrointestinal stromal tumor (GIST) in patients whose tumors lack common mutations. Researchers will analyze tumor samples from 50 people in Taiwan to find other genetic changes that might be treatable. The goal is to understand why some GISTs don't respond to standard drugs and to discover new treatment options.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal new genetic targets for treating wild type GIST, potentially leading to better therapies for this rare cancer.
What could go wrong
This is a small, early-stage observational study, not a treatment trial. It may not identify actionable genetic changes, and any findings would need further research to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2021

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Wild Type Gastrointestinal stromal tumor (GIST)

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pathologically confirmed GIST. 2. The tumors can be resected, unresectable, recurrent or metastatic and the patients had ever received, are receiving or will receive systemic treatment (adjuvant, neoadjuvant or salvage TKI or other targeted agents) 3. The tumors were tested for wild type c-KIT and PDGFRA. 4. There are archived tumor samples available or the patients agree to do tumor biopsy for oncopanel test if there is no tumor sample or not enough tumor sample available. 5. The patients who are systemic treatment naïve or have received prior systemic treatment are all eligible. 6. Age - the legal age. 7. Life expectancy greater than 6 months 8. Capable of understanding and complying with the protocol requirements and signed informed consent. Exclusion Criteria: * Patients will be excluded from the study if they meet any of the following criteria: 1. Inability and unwillingness to give informed consent 2. Patients do not agree to provide archived tumor samples and blood samples or they do not agree to do tumor biopsy when archived tumor samples are not available. 3. Patients refused for collection of clinical data and follow up. 4. Mental status is not fit for further treatment or data collection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal stromal tumor (GIST) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal stromal tumor (GIST)

Contacts and locations

Locations

  • Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan

  • Chang Gung Memorial Hospital

    Taoyuan, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, Taiwan

  • Mackay Memorial Hospital

    Taipei, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Tri-Service General Hospital

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.